Retina Associates of Kentucky Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT00955630
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

John Kitchens, MD

Active Ingredients

Drugs in Phase 2 Trials (2)

aflibercept (zaltrap) (1 trial)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 2)

Histoplasmosis (Phase 2)

Neovascularization, Pathologic (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2